IDiyas

For the Inventor, By the Inventor

Irvine, CA, United States of America

Julie Wurster

USPTO Granted Patents = 34 

 

Average Co-Inventor Count = 3.5

ph-index = 8

Forward Citations = 260(Granted Patents)


Company Filing History:

goldMedal33 out of 2,285 
 
Allergan, Inc.
 patents
silverMedal1 out of 228 
 
Allergan Sales, Inc.
 patents

Years Active: 2003-2017

Loading Chart...
Loading Chart...
34 patents (USPTO):Explore Patents
1. 9758509 - Substituted 3-(5-membered unsaturated heterocyclyl-1, 3-dihydro-indol-2-one's and derivatives thereof as kinase inhibitors (2017-09-12),
2. 9657005 - Substituted 3-(5-membered unsaturated heterocyclyl-1, 3-dihydro-indol-2-one's and derivatives thereof as kinase inhibitors (2017-05-23),
3. 9567324 - Substituted nicotinamide derivatives as kinase inhibitors (2017-02-14),
4. 9365575 - Kinase inhibitors (2016-06-14),
5. 9321766 - Kinase inhibitors (2016-04-26),
6. 9296747 - Piperidylpyrimidine derivatives as modulators of protein kinase inhibitors and of vascular endothelial growth factor receptor 2 (2016-03-29),
7. 9266869 - Substituted dialkyl(oxido)-lambda4-sulfanylidene nicotinamide derivatives as kinase inhibitors (2016-02-23),
8. 8969583 - 3-phenyl-5-ureidoisothiazole-4-carboximide and 3-amino-5-phenylisothiazole derivatives as kinase inhibitors (2015-03-03),
9. 8865682 - Substituted 3-(5-membered unsaturated heterocyclyl-1, 3-dihydro-indol-2-one's and derivatives thereof as kinase inhibitors (2014-10-21),
10. 8558002 - Sulfoximines as kinase inhibitors (2013-10-15),
11. 8455656 - Kinase inhibitors (2013-06-04),
12. 8455535 - Heteroaryl dihydroindolones as kinase inhibitors (2013-06-04),
13. 8455529 - Kinase inhibitors (2013-06-04),
14. 8383825 - Kinase inhibitors (2013-02-26),
15. 8338415 - Substituted 3-(5-membered unsaturated heterocyclyl-1, 3-dihydro-indol-2-one's and derivatives thereof as kinase inhibitors (2012-12-25),

Title: Innovations of Julie Wurster: A Leader in Kinase Inhibitors

Introduction

Julie Wurster, an accomplished inventor based in Irvine, California, holds an impressive portfolio of 34 patents. Her innovative work has made significant contributions to the field of pharmaceuticals, particularly in the development of kinase inhibitors that impact abnormal cell proliferation.

Latest Patents

Among her latest patents is the invention titled "Substituted 3-(5-membered unsaturated heterocyclyl-1, 3-dihydro-indol-2-one's and derivatives thereof as kinase inhibitors." This invention focuses on organic molecules capable of modulating tyrosine kinase signal transduction, highlighting her commitment to advancing therapeutic options in cancer treatment. This particular patent emphasizes the regulation, modulation, and inhibition of abnormal cell proliferation, showcasing Julie's dedication to addressing critical health issues.

Career Highlights

Throughout her career, Julie Wurster has worked with prominent companies such as Allergan, Inc. and Allergan Sales, Inc. Her role in these organizations has allowed her to apply her innovative ideas and lead efforts in developing new pharmaceutical solutions.

Collaborations

Julie has collaborated with esteemed colleagues like Thomas C. Malone and Steven Wade Andrews. These partnerships have enabled her to share insights and expertise, furthering the impact of her innovations in the industry.

Conclusion

Julie Wurster's contributions to the field of pharmaceuticals, particularly through her extensive patent portfolio, exemplify her role as a pioneering inventor. Her work continues to influence the development of effective treatment options, making her a noteworthy figure among contemporary innovators in the life sciences.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…